



Book nr	Presentation / publication	Title	Sessions / Topic	Presenter
PUBLICATIONS				
Epidemiology				
459	Publication	Real world and Mendelian Randomization Analyses of the Impact of autoimmune disease on clinical characteristics in lymphoma	Epidemiology	L. Zhan
460	Publication	Tobacco smoking impairs survival in lymphoma patients in two Finnish population-based cohorts	Epidemiology	T. Reunamo
461	Publication	ABO blood group type and risk of venous thromboembolism in patients with lymphoma	Epidemiology	D. Antic
462	Publication	Racial and ethnic representation in large B-cell lymphoma trials and real-world databases	Epidemiology	J. Munoz
463	Publication	Polatuzumab and the Progression-Free Survival (PFS) Predicament: A Comparative Analysis of Health Technology Assessment Agency (HTA) Reviews	Epidemiology	E. R S. Cliff
464	Publication	Clinical features and prognosis of patients coexisting with follicular lymphoma and diffuse large B-cell lymphoma: a retrospective observational study	Epidemiology	F. Zhu

Biology				
465	Publication	Single cell landscape of Multicentric Castleman Disease in identical twins	Biology	E. C. Y. Lee
466	Publication	A single-cell atlas of diffuse large B cell lymphoma	Biology	Q. Pan-Hammarström
467	Publication	Elucidating the molecular mechanisms of clonal evolution in multiple myeloma through single-cell RNA sequencing	Biology	J. Cui
468	Publication	PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma	Biology	X. Wang
469	Publication	ALK-positive large B-cell lymphoma is a terminally differentiated B-cell neoplasm featuring frequent epigenetic dysregulation and mutations involving MYC and the JAK-STAT pathway	Biology	X. Jiang
470	Publication	A 9-lncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-cell Lymphoma	Biology	X. Wang
471	Publication	The RNA m6A reader YTHDF2 regulates ACER2-ceramide metabolic axis to promote tumorigenesis of diffuse large B-cell lymphoma	Biology	X. m. Chen
472	Publication	KIAA1429 regulates Hippo-YAP pathway to maintain the tumorigenicity of diffuse large B-cell lymphoma via an m6A-dependent manner	Biology	X. m. Chen
473	Publication	NAT10 regulates the AMPK signaling pathway to promote DLBCL progression via ac4C acetylation of SLC30A9 mRNA	Biology	M. Ding
474	Publication	DNp73 Promotes drug Resistance and Immune Evasion in multiple myeloma via upregulating Myc and N-Myc	Biology	L. Liu
475	Publication	PTGDS Promotes Tumorigenesis of Peripheral T cell Lymphoma through Regulating Iron Metabolism	Biology	S. Hu

Microenvironment				
476	Publication	Pentose phosphate pathway inhibition activates macrophages towards phagocytic lymphoma cell clearance	Microenvironment	A. Beielstein
477	Publication	The association of the emerging tick-borne bacterial pathogen Neohrlichia mikurensis with malignant B cell lymphoma	Microenvironment	C. Wennerås
478	Publication	Patterns of circulating NK cell dysfunction in patients with lymphoma	Microenvironment	D. M. Ernst
479	Publication	Immune profile in the peripheral blood (PB) of patients with follicular lymphoma (FL) at diagnosis and upon relapse	Microenvironment	A. Rivero
480	Publication	m6A-Regulator expression signatures identify a subset of follicular lymphoma harboring an exhausted tumor microenvironment	Microenvironment	X. Wang
481	Publication	Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL	Microenvironment	H. Liu
482	Publication	Plasma Protein Profiling using Multiplex Extension Assay in DLBCL. A descriptive study exploring plasma protein pattern evolution in DLBCL treated with R-CHOP.	Microenvironment	A. H. Abu Sabaa
483	Publication	Traces of Epstein Barr virus (EBV) are not involved in the pathogenesis of Diffuse Large B cell lymphoma (DLBCL)	Microenvironment	T. S. Mangiaterra
484	Publication	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma	Microenvironment	X. Wang
485	Publication	Endothelial Activation and Stress Index is an independent prognostic factor of diffuse large B-cell lymphoma treated with standard immunochemotherapy	Microenvironment	R. Thanhakun

486	Publication	Identifying a novel defined pyroptosis-associated signature contributes to predicting prognosis and tumor microenvironment of diffuse large B-cell lymphoma	Microenvironment	L. Lv
487	Publication	Identification of tumor immune infiltration-associated snoRNAs for improving the prognosis of patients with diffuse large B-cell lymphoma	Microenvironment	X. Li
488	Publication	The roles of CD8 ⁺ CTLs, CD163 ⁺ TAMs, PDL1 in tumor microenvironment in the prognosis of primary central nervous system	Microenvironment	C. Wu
489	Publication	Relationship between gene mutation characteristics and tumor immune microenvironment in 18 cases of primary central nervous system lymphoma	Microenvironment	N. Yue
490	Publication	Classical Hodgkin Disease: presence of TIGIT mRNA in peritumoral lymphocytes	Microenvironment	O. Annibali
491	Publication	Global characterization of monocyte reveals a stress signature induced by multiple myeloma through single-cell RNA sequencing	Microenvironment	J. Cui
Translational studies (B-cell lymphomas, PTCL and cHL)				
492	Publication	Ultrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: analysis of efficacy and safety of 1000 bioptic procedures in a multicenter Italian study.	Translational	C. Giordano
493	Publication	Lymphoma diagnostic efficiency: predictors for diagnostic delay and prolonged referral to treatment time	Translational	L. Smyth
494	Publication	Impact of tumor mutational burden on the response to immunochemotherapy in follicular lymphoma	Translational	M. Lafuente
494 bis	Publication	The role of CD5 ⁺ as aggressive biomarker in diffuse large B-cell lymphoma	Translational	N. Rampi

495	Publication	Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia	Translational	F. Martin-Moro
496	Publication	Identify truly high-risk TP53-mutated DLBCL and explore the underlying biological mechanisms	Translational	J. Liang
497	Publication	Novel autoantibodies panel predicted prognosis of diffuse large B-cell lymphoma treated with R-CHOP therapy	Translational	L. Dai
498	Publication	Expression of Human Leukocyte Antigens genetic polymorphisms in patients with Diffuse Large B-Cell Lymphoma	Translational	E. Verrou
499	Publication	NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia	Translational	Y. Li
500	Publication	Increased soluble serum CD163 (sCD163) levels predict a short disease free survival in diffuse large B-cell lymphoma (DLBCL)	Translational	A. Koudouna
501	Publication	Characteristics and treatment outcomes of aggressive high grade B cell lymphoma with MYC and BCL6 rearrangements	Translational	J. Romejko Jarosinska
502	Publication	Prognostic significance of KAT2A as a histone acetylation regulator in diffuse large B-cell lymphoma	Translational	Z. Yu
503	Publication	Exploring the potential correlation between neutrophil extracellular traps and prognosis in patients with diffuse large B-cell lymphoma and Hodgkin's lymphoma	Translational	E. Pettersson
504	Publication	MYC alterations in HIV-Associated B Cell Lymphomas: results of "EUROMYC" Study (a European retrospective study)	Translational	C. Pagani

505	Publication	Exploring differential mutational distribution by targeted sequencing in a R-CHOP treated cohort of diffuse large B-cell lymphoma patients	Translational	G. Vimalathas
506	Publication	Enhancing morphological analysis of peripheral blood cells in chronic lymphocytic leukemia with an artificial intelligence-based tool	Translational	Y. Wang
507	Publication	Soluble Serum CD163(sCD163) levels is a marker of disease activity in Lymphoplasmacytic Lymphoma (LPL). Preliminary results.	Translational	A. Gkiokas
508	Publication	The incidence, clinical application and prognostic significance of MYD88 and CXCR4 mutation in Chinese patients with Lymphoplasmacytic lymphoma/ Waldenström Macroglobulinemia	Translational	Y. Yu
509	Publication	Prognostic significance of a novel amino acid metabolic index in chronic lymphocytic leukemia	Translational	M. Liu
510	Publication	Research on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)	Translational	L. Dai
511	Publication	Integrating multi-omics analysis and asparaginase activity curve to explain dramatic prognosis differences between early and advanced-stage in ENKTL patients	Translational	J. Liang
512	Publication	Integration of T-cell clonality screening using TRBC-1 in lymphoma suspect samples by flow cytometry	Translational	D. M. Ernst
513	Publication	Randomization is an infrequently used method in interventional phase II clinical trials of adult patients with lymphoma.	Translational	J. Díaz-Schmidt

Translational studies, liquid biopsy

514	Publication	Genomic aberrations detected in circulating tumor DNA from cerebrospinal fluid and plasma of patients with primary and secondary CNS lymphomas with negative flowcytometry	Liquid Biopsy and MRD	J. Kotaskova
515	Publication	Circulating tumor DNA measurement and total metabolic tumor volume by PET/CT as parameters for tumor burden and clinical response in diffuse large B-cell lymphoma.	Liquid Biopsy and MRD	G. Duffles
516	Publication	Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV+ DLBCL-NOS: a Chinese cohort study	Liquid Biopsy and MRD	J. Liang
517	Publication	Applicability Of Immunoglobulin Sequencing To Accurately Monitor Disease: An Analysis Of Uniqueness Among Diffuse Large B-Cell Lymphoma Patients Tested By clonoSEQ	Liquid Biopsy and MRD	A. Jacob
Imaging				
518	Publication	Combining baseline total metabolic tumor volume and beta-2-microglobulin levels predicts outcomes in high burden follicular lymphoma	Imaging	A. Zduniak
519	Publication	Prognostic value of metabolic parameters of baseline PET/CT in patients with double expression types of diffuse large B-cell lymphoma	Imaging	Z. J. Cheng
520	Publication	Prognostic significance of sequential 18F-FDG PET/CT during the treatment of anthracycline-containing frontline chemotherapy in peripheral T cell lymphomas	Imaging	G. Song
521	Publication	Investigating the safety and efficacy of IV fentanyl for brown fat mitigation in 18F-FDG-PET/CT in pediatric oncology: a multi-institutional experience	Imaging	J. Belsky

Hodgkin lymphoma				
522	Publication	Outcomes in elderly Hodgkin lymphoma: results from Korean multicenter cohort	HL	E. Lee
523	Publication	The low-risk early-stage Hodgkin Lymphoma patients with inadequate response to chemotherapy. The preliminary experience from the RAFTING trial	HL	K. Filonenko
524	Publication	Escalated BEACOPP x 2 + ABVD x 4 is superior to ABVD x 6 in advance stage classical Hodgkin lymphoma: experience in a tertiary center.	HL	X. MARTIN
526	Publication	Prospective Real world evidence: use of Brentuximab Vedotin as consolidation therapy after Autologous Transplant in Hodgkin Lymphoma. An interim analysis, on behalf of GATLA	HL	L. Fiad
527	Publication	Treatment strategies and prognostic factors for the outcome of patients with Hodgkin lymphoma experiencing Very Late Relapses after chemotherapy±radiotherapy	HL	T. P Vassilakopoulos
528	Publication	Late effects after treatment of Hodgkin Lymphoma, a single centre experience	HL	W. Bernard
529	Publication	Fertility preservation in adult lymphoma patients: a consensus-based position paper by the Fondazione Italiana Linfomi (FIL) & Società Italiana della Riproduzione Umana (SIRU)	HL	C. Minoia
530	Publication	Evaluation of gonadal function in young men and women diagnosed with Hodgkin Lymphoma	HL	A. N GEORGOPOULOU
531	Publication	My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.	HL	J. Trotman
Indolent lymphomas				
532	Publication	The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma	Indolent lymphomas	L. Su

533	Publication	Development and validation of a machine learning model for predicting early progression/relapse in follicular lymphoma	Indolent lymphomas	Y. Liu
534	Publication	Ki-67 Proliferation Patterns are Predictive of Early Progression and Inferior Outcomes in Grade 1-2 Follicular Lymphoma	Indolent lymphomas	A. E. Rojek
535	Publication	Clinical outcomes by progression of disease within 24 months (POD24) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with linterlisib	Indolent lymphomas	L. Qiu
536	Publication	Outcome of High dose chemotherapy plus autologous stem cell transplantation (HDT-ASCT) in relapsed/refractory Follicular Lymphoma: experience of a single Italian Institution.	Indolent lymphomas	A. Anastasia
537	Publication	Prospective Korean Marginal Zone Lymphomas Cohort Study: Initial data analysis of 407 cases	Indolent lymphomas	S. Y. OH
538	Publication	Comorbidity, age and sex in relation to survival among 2264 patients with Waldenstrom's macroglobulinemia – a Swedish Lymphoma Registry Study	Indolent lymphomas	L. Brandefors
539	Publication	Rituximab versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled phase 3 trial	Indolent lymphomas	S. Yi
540	Publication	Duodenal-type follicular lymphoma, a rare entity: clinical aspects, treatment and outcomes of Brazilian patients.	Indolent lymphomas	G. Duffles
541	Publication	Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia	Indolent lymphomas	W. Xiong
542	Publication	Combined modality ultra-low-dose adaptive radiotherapy and rituximab as treatment strategy for indolent non-hodgkin lymphomas: The UT Southwestern experience	Indolent lymphomas	M. Jackson

Extranodal lymphomas non MZL

543	Publication	Preliminary Findings of A Phase II study of Chemo-free combination of Pomalidomide, Orelabrutinib, Rituximab with Sequential high-dose Methorexate in Newly Diagnosed Primary CNS Lymphoma	Extranodal lymphomas	Y. Zhang
544	Publication	Autologous hematopoietic cell transplantation for primary central nervous system lymphoma (PCNSL). Real-world report of Polish Lymphoma Research Group.	Extranodal lymphomas	B. Ostrowska
545	Publication	A retrospective study of 222 patients with newly diagnosed primary CNS lymphoma - outcomes indicative for improved survival overtime	Extranodal lymphomas	O. Bairey
546	Publication	The role of upfront lenalidomide maintenance for primary central nervous system lymphoma patients responding to first-line MTX treatment	Extranodal lymphomas	Y. Zhang
547	Publication	Real World Experience of Primary Central Nervous System Lymphoma in a Multi-ethnic Asian Cohort	Extranodal lymphomas	Y. H. Tan
548	Publication	BTK inhibitors in CNSL and high-risk/refractory DLBCL patients: a real-world study	Extranodal lymphomas	L. Zhang
549	Publication	Efficacy and safety of BTK inhibitors in vitreoretinal lymphoma: a single-center retrospective analysis of 24 patients	Extranodal lymphomas	L. Wang
550	Publication	Efficacy and safety of first-line combination therapy versus monotherapy for primary vitreoretinal lymphoma: A systematic review and meta-analysis	Extranodal lymphomas	L. Wang
551	Publication	MR-guided adaptive radiotherapy for gastric lymphoma, preliminary results from ongoing study.	Extranodal lymphomas	P. M. Petersen
552	Publication	Radiation therapy in the management of primary gastric Diffuse Large B-Cell Lymphomas: long-term outcomes of 82 patients	Extranodal lymphomas	B. Fregonese

553	Publication	Clinical characteristics and pathological distribution in non-Hodgkin lymphoma of Waldeyer's ring from single institution in Cuba	Extranodal lymphomas	E. A. Gracia Medina
554	Publication	Clinicopathological characteristics of patients with non-Hodgkin lymphoma of the ocular adnexa.	Extranodal lymphomas	E. A. Gracia Medina
555	Publication	Primary Breast Lymphoma: Patient characteristics, treatment options and outcomes: a multi-center study of the Hellenic Cooperative Lymphoma Group	Extranodal lymphomas	C. Giatra
556	Publication	Clinical presentation, outcome, and prognostic factors in patients with intravascular large B- cell lymphoma: The Asia Experience From a single-center retrospective study	Extranodal lymphomas	Y. Zhang
557	Publication	Evaluation of fertility in women treated with the R-DA-EPOCH regimen for primary mediastinal B cell lymphoma (PMBCL)	Extranodal lymphomas	A. N. GEORGOPOULOU
558	Publication	Primary hepatic lymphoma: Role of low-dose radiotherapy and paired literature review	Extranodal lymphomas	J. Ma
Aggressive lymphomas				
559	Publication	Validation of Simplified Geriatric Assessment and Elderly Prognostic Index in Older Patients with Diffuse Large B-cell Lymphoma in China	Aggressive lymphomas	X. Yun
560	Publication	A population-based study reveals the unique clinical characteristics and long-term survival of patients with gray zone lymphoma	Aggressive lymphomas	X. Wang
561	Publication	Localized nodal Diffuse Large B Cell Lymphoma: is radiotherapy needed?	Aggressive lymphomas	A. C. Cortez
562	Publication	Front-line risk-adapted therapy presented favorable outcomes for young patients with diffuse large B-cell lymphoma: results from a consecutive cohort in China	Aggressive lymphomas	H. Zou

563	Publication	Daratumumab and EPOCH for HIV+/- plasmablastic lymphoma: a feasibility study of the AIDS Malignancy Consortium (AMC 105)	Aggressive lymphomas	A. Noy
564	Publication	Diffuse Large B-Cell Lymphoma: real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone in Cuba.	Aggressive lymphomas	E. A. Gracia Medina
565	Publication	CGA-driven therapeutic decision in elderly patients with previously untreated DLBCL in China: a multicenter, prospective, observational, controlled cohort study	Aggressive lymphomas	H. Liu
566	Publication	Efficacy and safety of Selinexor combining with R-CHOP in the treatment of untreated high risk (IPI 3-5) GCB subtype DLBCL patients: a multicenter real-world study from China.	Aggressive lymphomas	Z. Li
567	Publication	Pharmacokinetics, efficacy and safety of subcutaneous versus intravenous rituximab in Chinese patients with diffuse large B-Cell lymphoma: A randomized trial	Aggressive lymphomas	H. Huang
568	Publication	Check point inhibitors in relapsed/refractory gray zone lymphoma	Aggressive lymphomas	I. Dlouhy
569	Publication	The outcome of glofitamab therapy in patients with aggressive refractory B-NHL in real clinical practice	Aggressive lymphomas	L. Fedorova
570	Publication	Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)	Aggressive lymphomas	T. Rattanathammetee
571	Publication	Inferior outcomes with polatuzumab vedotin, bendamustine and rituximab for treatment of relapsed/refractory large B-cell lymphoma after >1 prior line of therapy	Aggressive lymphomas	W. Townsend
572	Publication	POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL-INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY	Aggressive lymphomas	E. Hawkes

573	Publication	Real-world outcomes with novel therapies in R/R DLBCL	Aggressive lymphomas	J. Crombie
574	Publication	CNS prophylaxis in patients with DLBCL: A Real World Experience on behalf of the Lymphoma Subcommittee of the Argentine Society of Hematology	Aggressive lymphomas	F. Warley
575	Publication	CNS relapse of diffuse large B-cell lymphoma and role of upfront prophylaxis: a 10-year single center experience.	Aggressive lymphomas	C. Benevolo Savelli
575 bis	Publication	Feasibility and safety of high-dose methotrexate intercalated with R-CHOP in diffuse large B-cell lymphoma: a single-center experience	Aggressive lymphomas	N. Rampi
576	Publication	High-dose methotrexate plus rchop: efficacy and toxicity in the prevention of central nervous system relapse in patients with diffuse large b cell lymphoma.	Aggressive lymphomas	M. CASADO
577	Publication	Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation (SOT): 15 years of monocentric experience in a referral Centre	Aggressive lymphomas	R. Cassin
578	Publication	Hypogammaglobulinemia at diagnosis is associated with inferior survival and higher risk of infections in diffuse large B cell lymphoma: a retrospective study from Sweden	Aggressive lymphomas	Å. Lindberg
579	Publication	Incidence and Predictive Factors of Platinum-associated Nephrotoxicity in Patients with Lymphoid Malignancies; A 15-year Experience Outside Clinical Trials	Aggressive lymphomas	J. Marquet
CLL				
580	Publication	A Multicenter Retrospective Study to Understand the Clinical Characteristics for Patients with Chronic Lymphocytic Leukemia: Interim Results from the CREEK Study	CLL	A. Al-Huraiji
581	Publication	A Multicenter Retrospective Study to Understand the Clinical Characteristics for Patients with Chronic Lymphocytic Leukemia: Asian Subgroup analysis of CREEK Study	CLL	B. P. Bagal

582	Publication	Clinical and biological features and outcomes of patients with chronic lymphocytic leukemia: a real-world study of 2005 patients in China	CLL	J. Chen
583	Publication	Low serum cholesterol level as a significant prognostic factor improves CLL-IPI in chronic lymphocytic leukemia	CLL	R. Gao
584	Publication	Identify the most commonly mutated genes in chronic lymphocytic leukemia and the significance on prognosis	CLL	W. Zhao
585	Publication	Comorbidity & CLL Different Scores – Different Results	CLL	V. Rathkolb
586	Publication	Real-world outcomes of patients (pt) with relapsed or refractory (R/R) CLL/SLL and prior treatment (tx) with both a Bruton tyrosine kinase inhibitor (BTKi) and venetoclax	CLL	J. Soumerai
587	Publication	Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China	CLL	Y. Yan
588	Publication	Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	CLL	S. Hakre
589	Publication	EPIC: A non-interventional, observational UK study of chronic lymphocytic leukemia (CLL) patients treated with first-line acalabrutinib. Interim analysis up to 24 months	CLL	T. A Eyre
590	Publication	Safety and effectiveness in R/R CLL patients treated with Venetoclax in combination with Rituximab under real-world conditions in Austria, Germany, and Switzerland	CLL	I. Schwaner
591	Publication	Matching-adjusted indirect comparison of pirtobrutinib vs venetoclax continuous monotherapy in patients with relapsed/refractory CLL treated with covalent BTK inhibitor	CLL	T. A Eyre
592	Publication	Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: A subgroup of ALPINE	CLL	L. Qiu

593	Publication	A matching-adjusted indirect comparison of the efficacy and safety of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia	CLL	P. Ghia
594	Publication	A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL)	CLL	N. Bahar
595	Publication	Patterns of Immunoglobulin G Testing and Infection Outcomes in Patients With Chronic Lymphocytic Leukemia Receiving Immunoglobulin Replacement Therapy	CLL	J. D Soumerai
596	Publication	Retrospective study of burden of infection in patients with and without secondary immunodeficiency disease following diagnosis of chronic lymphocytic leukaemia	CLL	M. S Davids
MCL				
597	Publication	Soluble macrophage marker sCD163 predicts outcome in both chemoimmunotherapy and targeted therapy treated mantle cell lymphoma	MCL	A. Nikkarinen
597 bis	Publication	MIPI53. A new prognostic index for mantle cell lymphoma	MCL	M. Bastos Boente
598	Publication	Type of ATM aberration has a different impact on survival parameters in mantle cell lymphoma	MCL	A. Obr
599	Publication	STAGE I-II MANTLE CELL LYMPHOMA: CHARACTERISTICS AT DIAGNOSIS, THERAPY USED AND OUTCOME	MCL	S. Verdesoto Cozzarelli
600	Publication	Orelabrutinib-lenalidomide-rituximab (OLR) in patients with untreated mantle cell lymphoma (MCL): a prospective, multicenter, single-arm phase 2 POLARIS study in China	MCL	H. Zhang
601	Publication	Zanubrutinib Plus Bendamustine and CD20 monoclonal antibody As Treatment for Mantle Cell Lymphoma	MCL	S. Qin
602	Publication	LIFETIME TREATMENT BURDEN OF PATIENTS WITH MANTLE CELL LYMPHOMA: SIMULATION-BASED ANALYSIS OF REAL-WORLD DATA FROM 20 YEARS	MCL	M. E. Harmanen

603	Publication	Unmet need in relapsed/refractory (R/R) mantle cell lymphoma (MCL) post-Bruton tyrosine kinase inhibitor (BTKi): A systematic literature review and meta-analysis	MCL	M. Dreyling
604	Publication	Treatment patterns in patients with mantle cell lymphoma: Updated Report of the Asia-Pacific multinational retrospective registry study	MCL	W. S. Kim
605	Publication	Comparison of bleeding-related events in patients who received pirtobrutinib with and without antithrombotic agents	MCL	W. Jurczak
606	Publication	Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: a network meta-analysis of randomized controlled trials	MCL	C. Jing
PTCL				
607	Publication	Peripheral T Cell Lymphoma (PTCL) and treatment out-come Single centre retrospective study	PTCL	S. S. Samuel
608	Publication	How we are successful in therapy of T-cell lymphoma patients (≥ 70 years). Real-world analysis from the Czech lymphoma study group registry (NIHIL).	PTCL	A. Janikova
609	Publication	Brentuximab vedotin in combination with chemotherapy in patients with newly diagnosed CD30-positive peripheral T-cell lymphomas: real-world data	PTCL	M. Klanova
610	Publication	Analysis of patients in the first relapse or progression of T-cell lymphoma. Real world data from Czech lymphoma study group registry (NIHIL).	PTCL	A. Janikova
611	Publication	A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) in the autologous stem cell transplantation of aggressive T-cell lymphoma	PTCL	J. Ji
612	Publication	A real-world study of Chidamide for patients with peripheral T-cell lymphoma in China	PTCL	X. Wang
613	Publication	Clinical efficacy of CD34 positive selection ex-vivo purging during autologous stem cell transplantation in peripheral T cell lymphoma	PTCL	Y. Jeon

614	Publication	Preliminary results of gemcitabine, etoposide, mitoxantrone hydrochloride liposome and dexamethasone regimen for newly diagnosed early NUAT or advanced stage ENKTL	PTCL	J. Liang
615	Publication	A multi-center retrospective study of pembrolizumab in patients with relapsed or refractory extranodal nk/t-cell lymphoma	PTCL	J. Y. Lee
616	Publication	The outcome of modified-SMILE regimen as the first-line treatment for newly diagnosed frail advanced high-risk NK/T cell lymphoma: a retrospective observation study	PTCL	F. Zhu
617	Publication	Preliminary results of a phase 2 study of chidamide, gemcitabine, vinorelbine, and mitoxantrone liposome (Chi-GVM) in relapsed/refractory peripheral T-cell lymphoma	PTCL	H. Yin
618	Publication	Single agent Brentuximab Vedotin as bridge to allogeneic stem cell transplant in adolescents with relapsed anaplastic large cell lymphoma (ALCL): the UCLH experience	PTCL	V. Fiaccadori
619	Publication	Lymph node and skin scoring growth kinetics predict outcomes in cutaneous T-cell lymphoma: an interim analysis	PTCL	L. M. Fahmy
620	Publication	A case series of patients with cutaneous T-cell lymphoma treated with combination mogamulizumab and other therapies after single agent mogamulizumab	PTCL	R. Treitman
621	Publication	Excellent outcomes of subcutaneous panniculitis-like T-cell lymphoma treated with cyclosporin-based regimen, a multicenter retrospective study in Thailand	PTCL	P. Noiperm
622	Publication	Optimising holistic care of women at risk of or living with BIA-ALCL: a survey of UK health care professionals.	PTCL	E. J. Elwood
Plasma cell neoplasms and amyloidosis				
623	Publication	Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma	Plasma cell neoplasms	T. Fang

624	Publication	Kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) are expressed on B cell malignancies and are promising novel targets on malignant plasma cells	Plasma cell neoplasms	D. Gottlieb
625	Publication	A predictive model for ultra-high risk in patients with newly diagnosed multiple myeloma: a single-center study in China	Plasma cell neoplasms	L. Zhang
626	Publication	Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in patients with newly-diagnosed multiple myeloma	Plasma cell neoplasms	W. Yan
627	Publication	Stem cell mobilization and autologous stem cell transplantation after bendamustine, prednisone and bortezomib induction in multiple myeloma patients with renal impairment	Plasma cell neoplasms	S. Wang
628	Publication	Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy	Plasma cell neoplasms	H. S. Ababneh
629	Publication	Upfront radiation therapy for post-stem cell transplant multiple myeloma patients with oligo-relapse/progressive disease: factors associated with favorable outcomes	Plasma cell neoplasms	B. Fregonese
630	Publication	Intermediate-dose AraC+G-CSF is more effective than Cy+G-CSF and Plerixafor+G-CSF in hematopoietic stem cell mobilization in poor mobilizers	Plasma cell neoplasms	S. Elkhova
631	Publication	Autologous stem cell transplantation in patients with newly diagnosed multiple myeloma with dialysis-dependent renal impairment	Plasma cell neoplasms	I. Kliuchagina
CAR-T (Cellular therapies)				
632	Publication	Phase-2 First-in-India Industry Study of Varnimcabtogene Autoleucel (IMN-003A) in Relapsed Refractory B Cell Malignancies: IMAGINE Study B-NHL Subanalysis	CAR T-cell and other cellular therapies	S. Damodar

633	Publication	Preliminary Data from a First-in Human Phase II Study of Sequential Use of Selinexor and CD19 CART Therapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin lymphoma	CAR T-cell and other cellular therapies	C. Li
634	Publication	Durable long-term remission in high-risk relapse refractory lymphoma - 20 years' experience of allogeneic haemopoietic stem cell transplant in Singapore	CAR T-cell and other cellular therapies	J. Loke
635	Publication	Remission after CAR T-cells: do patients recover a normal life?	CAR T-cell and other cellular therapies	P. Alya
636	Publication	Real-world outcomes of intravenous immunoglobulin for hypogammaglobulinemia after chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma	CAR T-cell and other cellular therapies	D. S Chun
637	Publication	Comparative Effectiveness of Salvage Chemotherapy and Chimeric Antigen T-cell Receptor Therapies in R/R DLBCL: A Systematic Review and Network Meta-Analysis	CAR T-cell and other cellular therapies	I. Y Gong

638	Publication	Salvage Treatments for Relapsed/Refractory Secondary CNS Lymphoma in the CAR T Era: A Real-World Comparison	CAR T-cell and other cellular therapies	A. M. Patel
639	Publication	Comparison of the efficacy of epcoritamab versus chimeric antigen receptor therapies, polatuzumab-based regimens, and tafasitamab-based regimens	CAR T-cell and other cellular therapies	A. Rosenthal
640	Publication	Outcomes of the treatment after anti-CD19 CAR-T therapy failure in patients with aggressive B-cell lymphoma - analysis of data from the Czech Republic	CAR T-cell and other cellular therapies	A. Sýkorová
Preclinical new drugs				
641	Publication	A novel anthracycline MNPR-202 displays a distinct immunomodulatory profile to doxorubicin in diffuse large B cell lymphoma	Preclinical New Drugs	M. Liu
642	Publication	APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations	Preclinical New Drugs	Y. Fei
643	Publication	NX-0255 and NX-1607, small molecule inhibitors of CBL-B, are efficacious in combination with adoptive cell therapy or Rituximab in preclinical mouse models of lymphoma	Preclinical New Drugs	M. Gallotta
644	Publication	BV6, an antagonist of inhibitor of apoptosis proteins, sensitizes resistant mantle cell lymphoma cells to venetoclax	Preclinical New Drugs	Y. Liu

645	Publication	Combination Strategies Overcome Treatment Resistance Driven by Gain-of-Function BCL10 Mutations in Diffuse Large B-Cell Lymphoma	Preclinical New Drugs	C. A. Coughlin
646	Publication	LYMPHOMA TISSUE EXPLANTS TO ANTICIPATE RESPONSE TO TARGETED THERAPIES	Preclinical New Drugs	J. Epiney
647	Publication	Creation of isogenic cell line models of 17p deletion to study clonal evolution and mechanisms of therapy resistance in CLL and DLBCL.	Preclinical New Drugs	F. L. van Kampen
648	Publication	CRIP1 Induces Pls Resistance by Forming a Complex With USP7 /PA200 and Enhancing Proteasome Activity and Autophagy in Multiple Myeloma	Preclinical New Drugs	M. Hao
649	Publication	Nanosecond pulsed electric field modulates immunophenotype of lymphocytes	Preclinical New Drugs	N. Sauer
650	Publication	Effects of Alternating Magnetic Field on the Expression of Activation Markers CD154 and CD69 in Jurkat Cell Line.	Preclinical New Drugs	W. K. Szlasa
651	Publication	CRISPR/Cas9 screening reveals SOS1 participate in asparaginase resistance in NK/T cell lymphoma	Preclinical New Drugs	D. Wang
652	Publication	A hybrid energy- and AI-based screening for novel inhibitors of LCK for the treatment of T-cell lymphoblastic lymphoma	Preclinical New Drugs	H. Guo
Phase I-II				
653	Publication	Updated results from a phase 1b study of amdizalisib, a novel inhibitor of phosphoinositide 3-kinase-delta (PI3K δ), in patients with relapsed or refractory lymphoma	Phase I-II trials	J. Cao
654	Publication	Activity and safety of preclinical and a phase 1 study of purinostat mesylate, a uniquely potent and selective HDAC I/IIb inhibitor in relapsed or refractory lymphoma	Phase I-II trials	J. Wang

655	Publication	Treatment of B-cell malignancies with DZD8586 through overcoming both BTK-dependent and BTK-independent resistance	Phase I-II trials	K. Zhou
656	Publication	Preclinical and a phase 1 study of purinostat mesylate, a novel HDAC I/IIb selective inhibitor, for the treatment of relapsed or refractory multiple myeloma	Phase I-II trials	J. Wang
657	Publication	Phase 1 trial of KT-413, a degrader of IRAK4 and IMiD substrates, in adult patients with relapsed or refractory B-cell Non-Hodgkin's lymphomas	Phase I-II trials	J. K. Lue
658	Publication	Selinxor combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL) (SWATCH study)	Phase I-II trials	L. Wang
659	Publication	ORIENT study: regimen of orelabrutinib plus R-CHOP-like for patients with newly diagnosed untreated non-GCB DLBCL	Phase I-II trials	C. Qu
660	Publication	Phase I Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Patients in Incomplete Response after CAR-T Therapy	Phase I-II trials	P. Ramakrishnan Geethakumari
661	Publication	Correlation between somatic mutations and prognosis in pediatric mature B-cell lymphoma	Phase I-II trials	Y. Liu
Infections				
662	Publication	The incidence of interstitial pneumonia in newly treated diffuse large B-cell lymphoma patients during the COVID-19 pandemic: a single-center, retrospective analysis of consecutive cases	Infection	L. Wang
663	Publication	Low mortality from COVID-19 in patients with B cell lymphoma after bispecific CD3 x CD20 therapy.	Infection	E. R. Kyvsgaard
664	Publication	Repeated vaccination to maximum antibody response and anti-viral therapy in CLL and MBL result in very low COVID mortality and hospitalisation rates	Infection	Y. Shen

665	Publication	Factors influencing survival and prolonged viral replication in patients with lymphoma and COVID-19: An observational cohort study from GELTAMO Spanish group.	Infection	A. Cabero-Martínez
666	Publication	Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: a population-based analysis	Infection	I. Y Gong
667	Publication	Identifying factors that affect barriers to lymphoma treatment during the COVID - 19 pandemic	Infection	N. Bolanos
669	Publication	TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE	Infection	L. Pezzullo
670	Publication	B cells with virus-neutralizing IGHV1-69 mutations show lymphoma-like transcriptomes in patients with chronic hepatitis C infection	Infection	C. Schultheiß
671	Publication	Different types of antiviral therapy (AVT) in patients with viral hepatitis C-associated diffuse B-cell lymphoma (HCV+DVCL)	Infection	S. Lepkov
672	Publication	Incidence of HBV reactivation in patients with Diffused large B cell lymphoma in era of prophylactic antiviral therapy	Infection	R. Nuersulitan
673	Publication	Vaccination Strategies for patients with lymphoma: a real-world practice survey among Fondazione Italiana Linfomi centers	Infection	O. Annibali
Ongoing trials				
OT07	Publication	Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)	Ongoing trials	B. T. Hess
OT08	Publication	NATHALI-01: a phase 1/2a trial of UCART20x22, an allogeneic dual CAR T-cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL)	Ongoing trials	E. Bachy

OT09	Publication	A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients with Relapsed or Refractory B-Cell Lymphomas	Ongoing trials	B. S. Imber
OT10	Publication	Epcoritamab monotherapy and combinations in relapsed or refractory chronic lymphocytic leukemia or Richter's syndrome: new escalation and expansion cohorts in EPCORE CLL-1	Ongoing trials	B. Eichhorst
OT11	Publication	A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies	Ongoing trials	B. D. Cheson
OT12	Publication	A phase 1/2 study of STP938, a first in class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma	Ongoing trials	M. Ahearne
OT13	Publication	SGR-1505-101: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of SGR-1505 as Monotherapy in Subjects with Mature B-Cell Malignancies	Ongoing trials	A. olszewski
OT14	Publication	ETCTN P10500: Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma	Ongoing trials	J. E. Amengual
OT15	Publication	Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B-cell malignancies	Ongoing trials	S. E. Assouline
OT16	Publication	Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Lymphoma	Ongoing trials	A. Mc Allister
OT17	Publication	Smart Stop: A phase II clinical trial of lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with response adapted chemotherapy in patients with newly diagnosed DLBCL	Ongoing trials	J. Westin
OT18	Publication	KILT: a randomized non-comparative phase II LYSA study of Lacutamab with GemOx versus GemOx in relapsed/refractory Peripheral T-cell Lymphoma	Ongoing trials	M. Cheminant

OT19	Publication	SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma	Ongoing trials	B. Hess
OT20	Publication	A randomized Phase II study of MB-CART2019.1 compared to standard of care in patients with relapsed/refractory DLBCL ineligible for ASCT – DALY 2-EU Trial	Ongoing trials	P. Borchmann
OT21	Publication	P+R-ICE: Pembrolizumab in combination with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma - Ongoing trial	Ongoing trials	L. Stanton
OT22	Publication	S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL	Ongoing trials	J. E. Amengual
OT23	Publication	ZUMA-24: a Phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given outpatient with corticosteroids	Ongoing trials	L. Leslie
OT24	Publication	Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone in patients with relapsed or refractory Peripheral T-cell Lymphomas (R/R PTCLs)	Ongoing trials	A. Chiappella
OT25	Publication	Trial in Progress: Odronextamab, a CD20×CD3 bispecific antibody, for the treatment of relapsed/refractory marginal zone lymphoma (R/R MZL) – a cohort from the ELM-2 study	Ongoing trials	S. Cho
OT26	Publication	R-CHOP with Sintilizumab in First-Line Treatment of Large B-Cell Lymphoma Patients with TP53 Mutations and PD-L1 expression: A Randomized, Multicenter Clinical Study	Ongoing trials	Y. Che
OT27	Publication	Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas	Ongoing trials	E. A Brem
OT28	Publication	Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2	Ongoing trials	L. H Sehn

OT29	Publication	LOTIS-5, an ongoing phase 3 randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL	Ongoing trials	C. Carlo-Stella
OT30	Publication	A Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Patients with High Risk Chronic Lymphocytic Leukemia	Ongoing trials	N. Kutsch
OT31	Publication	ZUMA-22: A Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel (Axi-Cel) vs Standard-of-Care Therapy in Patients With Relapsed/Refractory Follicular Lymphoma	Ongoing trials	I. W. Flinn
OT32	Publication	Discovering targetable immune populations in Cutaneous T-cell Lymphoma	Ongoing trials	A. Johansson
OT33	Publication	Onkofrail: personalization of a physical exercise program in older patients with lymphoma	Ongoing trials	M. MARTINEZ DE RITUERTO ZEBERIO